Dainippon’s Lead Boston Asset Hits Wall In Pancreatic Cancer
Dainippon Sumitomo suffers major Phase III setback for one of its key oncology prospects, and although the former Boston Biomedical asset will carry on in other planned indications, the Japanese firm may have to look for ways to fill the gap.
You may also be interested in...
Vant deal, discovery platforms help Japanese firm build out pipeline before it faces the first expiries for its top seller.
Looking back on the top stories about Japan in Scrip and the Pink Sheet over 2019, it is hard to avoid the continued dominance of corporate transactions - in particular those involving Takeda.
Facing looming expiries for its top product, Japan’s Sumitomo Dainippon is planning to acquire multiple "vant" companies and their portfolios of clinical stage assets from Roivant, in a move to address mid-term challenges to revenues and following recent late-stage development failures.